Showing 5481-5490 of 5643 results for "".
- Oculis Elects Anthony Rosenberg and David A. Weber to Its Board of Directorshttps://modernod.com/news/oculis-elects-anthony-rosenberg-and-david-a-weber-to-its-board-of-directors/2479867/Oculis announced the appointments of Anthony Rosenberg as Non-Executive Chairman and David A. Weber, PhD, as Non-Executive Director. Together, they bring more than 60 years’ experience from the global pharmaceutical and eye care industries to the compa
- IOT Launches New Corporate Brandinghttps://modernod.com/news/iot-launches-new-corporate-branding/2479870/Optical technology company IOT has announced a change in brand identity as part of an overall strategy to better communicate its culture, values, and approach to market. The new website and social media profiles are designed to help the company share optical knowledge as well as information abou
- Positive PEACHTREE Data to be Highlighted at Euretina 2018https://modernod.com/news/positive-peachtree-data-to-be-highlighted-at-euretina-2018/2479871/Clearside Biomedical announced that data from PEACHTREE, its pivotal phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Ron Neumann, MD, Uveitis Specialist at Maccabi Health Services, Tel Aviv, Israel and co-Chair of
- Allergan Announces New Partnership With the International Diabetes Federationhttps://modernod.com/news/allergan-announces-new-partnership-with-the-international-diabetes-federation/2479873/Allergan has announced a collaborative partnership with the International Diabetes Federation (IDF) with the aim of developing a global approach to screen, diagnose, and manage diabetic macular edema (DME). Diabetic eye health is a key concern for IDF and Allergan. The partnership will bri
- Neurolens Appoints Thomas J. Chirillo as Chief Commercial Officerhttps://modernod.com/news/neurolens-appoints-thomas-j-chirillo-as-chief-commercial-officer/2479876/Neurolens announced the appointment of Thomas J. Chirillo as Chief Commercial Officer. An accomplished senior healthcare executive with deep experience in the eye care space, Mr. Chirillo brings almost 4 decades of sales and marketing experience to neurolens. “We’re thrilled to have someon
- FDA Grants Lin BioScience Rare Pediatric Disease Status for LBS-008 to Treat Stargardt Diseasehttps://modernod.com/news/fda-grants-lin-bioscience-rare-pediatric-disease-status-for-lbs-008-to-treat-stargardt-disease/2479877/Lin BioScience announced that the FDA has granted rare pediatric disease (RPD) designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease. The Priority Review Voucher Program is intended to encourage development of therapies to prevent and treat rare pedi
- Diopsys Highlights Educational Initiatives For ESCRS 2018https://modernod.com/news/diopsys-highlights-educational-initiatives-for-escrs-2018/2479883/Diopsys announced educational initiatives for the ESCRS 2018 Congress in Vienna, Austria, September 22-26. In addition to presentations that highlight how the various forms of testing available on Diopsys devices add to the management of eye care patients, the company will also be introducing the
- Ziemer to Implement Low Energy Lenticule Extraction Applications for its Femtosecond Laser Platformhttps://modernod.com/news/ziemer-announces-to-implement-low-energy-lenticule-extraction-applications-to-its-femtosecond-laser-platform/2479888/Ziemer Ophthalmic Systems announced plans to incorporate lenticule extraction capabilities for its flagship LDV Z8 femtosecond laser system.1 “From the very first days of developing the femtosecond l
- FDA to Review Eylea (Aflibercept) Injection for the Treatment of Diabetic Retinopathyhttps://modernod.com/news/fda-to-review-eylea-aflibercept-injection-for-the-treatment-of-diabetic-retinopathy/2479893/Regeneron Pharmaceuticals announced that the FDA has accepted for review the supplemental biologics license application of Eylea (aflibercept) injection for the treatment of diabetic retinopathy (DR). The target action date for the FDA decision is May 13, 2019. The supplemental biologics l
- Alcon Adds New Ultraviolet-Absorbing Only IOL Options to its AcrySof Portfoliohttps://modernod.com/news/alcon-adds-new-ultraviolet-absorbing-only-iol-options-to-its-acrysof-portfolio/2479895/Alcon expanded its AcrySof IOL portfolio with the introduction of multifocal and multifocal toric ultraviolet (UV)-absorbing IOLs, as well as the introduction of the AcrySof UV-Absorbing monofocal IOL with the UltraSert Preloaded Delivery System. “At Alcon, input from our surgeons is at th